Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 6Terminated 2Withdrawn 1Unknown 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Plasma cell 2Myeloid 2Gynecologic 2Gastrointestinal 2Breast 2Other hematologic neoplasm 1Lymphoid 1Genitourinary 1CNS 1

Conditions

Pancreatic Neoplasms 100Carcinoma, Non-Small-Cell Lung 48Neoplasms 34Urinary Bladder Neoplasms 25Lung Neoplasms 25Cholangiocarcinoma 23Breast Neoplasms 22Neoplasm Metastasis 21Ovarian Neoplasms 18Lymphoma, Non-Hodgkin 13Lymphoma 13Recurrence 12Lymphoma, Large B-Cell, Diffuse 11Biliary Tract Neoplasms 11Sarcoma 10Carcinoma, Transitional Cell 9Hodgkin Disease 8Gallbladder Neoplasms 8Fallopian Tube Neoplasms 8Adenocarcinoma 8Bile Duct Neoplasms 7Colorectal Neoplasms 6Triple Negative Breast Neoplasms 5Lymphoma, Follicular 5Liver Neoplasms 5Head and Neck Neoplasms 5Carcinoma, Renal Cell 5Adenocarcinoma of Lung 5Uterine Cervical Neoplasms 4Small Cell Lung Carcinoma 4

Interventions

Dexamethasone 112Bortezomib 61Lenalidomide 49Cyclophosphamide 49Calcium Dobesilate 43pomalidomide 32Melphalan 31fludarabine 25Filgrastim 25carfilzomib 22fludarabine phosphate 21daratumumab 20Granulocyte Colony-Stimulating Factor 16Whole-Body Irradiation 15Antilymphocyte Serum 15dexamethasone acetate 14Mycophenolic Acid 14Thalidomide 13Tacrolimus 13Cyclosporine 13Busulfan 13Peripheral Blood Stem Cell Transplantation 12ixazomib 11dexamethasone 21-phosphate 10auricularum 10pembrolizumab 9Radiotherapy 9Etoposide 9belantamab mafodotin 8Rituximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Multiple Myeloma × Gemcitabine × Clear all
NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Incyte Corporation

Phase 1/2 Terminated
201 enrolled 71 charts
BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡